APPLICATION OF NEURAMINIDASE AND INHIBITORS THEREOF IN MYOCARDIAL ISCHEMIA AND MYOCARDIAL INFARCTION

• US 20190054055A1
• Filed: 03/29/2016
• Published: 02/21/2019
• Est. Priority Date: 03/22/2016
• Status: Active Grant

• Current Assignee: China Pharmaceutical University
• Original Assignee: China Pharmaceutical University
• Inventors: QI, Lianwen, ZHANG, Lei, WEI, Tingting, FAN, Yong
• Granted Patent: US 10,639,289 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/351 not condensed with another ring
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/4375 the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• CPC Class Codes: A61K 31/7012 Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid gluconic acid A61K31/191; ascorbic acid A61K31/375
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.

Claims

1. A method of preventing, alleviating, or treating myocardial ischemic damage in a subject, comprising:

administering an effective amount of a pharmaceutical composition to the subject in need thereof;

wherein the pharmaceutical composition contains a compound that inhibits the activity of neuraminidase; and

the compound excludes coptisine.

5. The method preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 1, wherein the compound is a zanamivir.

6. The method preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 1, wherein the compound is an oseltamivir phosphate.

8. The method preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 1, wherein the compound is a combination of a zanamivir and a coptisine.

9. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 1, wherein the compound is a combination of an oseltamivir phosphate and a coptisine.

10. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 1 wherein the myocardial ischemic damage is myocardial ischemia caused by myocardial infarction.

12. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 6, wherein the myocardial ischemic damage is myocardial ischemia caused by myocardial infarction.

13. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 8, wherein the myocardial ischemic damage is myocardial ischemia caused by myocardial infarction.

14. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim 9, wherein the myocardial ischemic damage is myocardial ischemia caused by myocardial infarction.

2. (canceled)

3. (canceled)

4. (canceled)

7. (canceled)

11. The method of preventing, alleviating, or treating myocardial ischemic damage in a subject according to claim wherein the myocardial ischemic damage is myocardial ischemia caused by myocardial infarction.